本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Sarepta Therapeutics

54.63
+3.607.05%
盘后54.50-0.1300-0.24%19:49 EDT
成交量:231.06万
成交额:1.24亿
市值:53.01亿
市盈率:23.36
高:54.64
开:53.34
低:51.39
收:51.03
数据加载中...
2025/03/12

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/02/28

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/02/27

重要事件披露

Form 8-K - Current report
2025/02/14

重要事件披露

Form 8-K - Current report
2025/01/13

重要事件披露

Form 8-K - Current report
2024/12/12

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/12/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/26

重要事件披露

Form 8-K - Current report
2024/11/13

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/06

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/09/16

重要事件披露

Form 8-K - Current report
2024/08/30

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/07

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/08/07

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/06/25

关联方拟减持公告

Form144|赛普拉高管Bilal Arif拟减持3898股,总价约63.9万美元
2024/06/25

关联方拟减持公告

Form144|赛普拉高管Ryan Brown拟减持38957股,总价约638万美元
2024/06/24

关联方拟减持公告

Form144|赛普拉高管Bilal Arif拟减持7859股,总价约126万美元
2024/06/07

重要事件披露

Form 8-K - Current report
2024/05/01

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/03/28

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments